MODULATION THERAPEUTICS, INC.

Address

2711 CENTERVILLE RD, STE 400
WILMINGTON, DE, 19808-1645

http://modulationtherapeutics.com/default.html

Information

DUNS: 968675244
# of Employees: 3

Ownership Information

Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N

Award Charts




Award Listing

  1. Novel SCD1 inhibitors for treatment of cancer

    Amount: $279,000.00

    DESCRIPTION provided by applicant Metastatic clear cell renal cell carcinoma mccRCC is an incurable cancer with a year survival of less than for which novel therapeutic agents need to be d ...

    STTRPhase I2016Department of Health and Human Services
  2. IGF OT IGF SBIR TOPIC

    Amount: $299,336.00

    Not Available

    SBIRPhase I2015Department of Health and Human Services National Institutes of Health
  3. Targeting CD137L to MC1R-Expressing Melanoma Cells and Tumors.

    Amount: $244,801.00

    DESCRIPTION provided by applicant There are specific high affinity ligands for receptors found on many cancers that have been investigated as imaging probes and we believe that we should try to enh ...

    STTRPhase I2015Department of Health and Human Services National Institutes of Health
  4. Second generation MTI-101 analogs using a novel peptoid-peptide hybrid beta-hairp

    Amount: $225,000.00

    MTI-101 is a cyclic beta-hairpin peptide that binds CD44 with high affinity and kills multiple myeloma cell lines in vitro and blocks the growth of myeloma tumors in 2 different murine models. This in ...

    STTRPhase I2014Department of Health and Human Services
  5. A Virtually Supervised Web-Based Home Exercise Technology for Older Adults

    Amount: $288,301.00

    DESCRIPTION (provided by applicant): The majority of multiple myeloma (MM) patients will initially respond to standard chemotherapy. However, eventually relapse of the disease, associated with a multi ...

    SBIRPhase I2013Department of Health and Human Services
  6. Chemical Optimization Designed to Increase the in vivo Efficacy of HM-27 for the

    Amount: $156,202.00

    DESCRIPTION (provided by applicant): This application requests funds to aid in obtaining the necessary additional preclinical data needed for commercialization of a promising new and novel drug candid ...

    SBIRPhase I2012Department of Health and Human Services
  7. Targeting CD44 in the bone marrow microenvironment of MM

    Amount: $218,817.00

    DESCRIPTION (provided by applicant): The majority of multiple myeloma (MM) patients will initially respond to standard chemotherapy. However, eventually relapse of the disease, associated with a multi ...

    SBIRPhase I2012Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government